BeyondSpring's Plinabulin Shows Promise in Reversing Immune Checkpoint Inhibitor Resistance Across Multiple Cancer Types
Key Insights
BeyondSpring published a clinical study in Med (Cell Press) demonstrating that Plinabulin, combined with radiation and checkpoint inhibitors, induces dendritic cell maturation and elicits tumor responses in patients who had failed prior immune checkpoint inhibitor therapy.
The study achieved a 23% overall response rate and 54% disease control rate in non-irradiated lesions, suggesting promising clinical activity for treatment-resistant cancers.
Researchers identified that Plinabulin works through the GEF-H1 (search)–dependent pathway to mature dendritic cells, potentially allowing prediction of patient response through baseline GEF-H1 immune signature analysis.
BeyondSpring Inc. has published groundbreaking clinical data demonstrating that its investigational drug Plinabulin can reverse resistance to immune checkpoint inhibitor (ICI) therapy when combined with radiation and checkpoint inhibitors. The human clinical study, published in Med (Cell Press) on July 7, 2025, represents a significant advancement in treating patients with multiple cancer (search) types who have exhausted standard immunotherapy options.
Breakthrough in Overcoming Treatment Resistance
The clinical study revealed that Plinabulin induces dendritic cell (DC) maturation and elicits tumor responses in patients across multiple cancer (search) types who had failed prior ICI therapy. The treatment achieved an overall response rate of 23% and a disease control rate of 54% in non-irradiated lesions, demonstrating promising clinical activity in a challenging patient population.
Researchers discovered that Plinabulin works through the GEF-H1 (search)–dependent pathway to mature dendritic cells, a mechanism that could enable physicians to predict which patients will benefit from the treatment by examining a baseline GEF-H1 immune signature. Dr. Steven Lin highlighted the potential of this new approach to reverse resistance to ICI therapy, indicating that Plinabulin could offer renewed hope for patients with treatment-resistant cancers.
Phase 2 Data Shows Strong Survival Benefits
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, BeyondSpring presented interim Phase 2 data from its 303 Study, focusing on patients with metastatic non-small cell lung cancer (search) (NSCLC (search)) who experienced disease progression after first-line treatment with PD-1 (search)/L1 inhibitors. The study, supported by Merck (search)'s Investigator Studies Program, evaluated 47 patients treated with the triple combination of Plinabulin, pembrolizumab, and docetaxel.
The results demonstrated a median progression-free survival of 6.8 months and a 15-month overall survival rate of 78%. These findings suggest that the triple therapy might help re-sensitize tumors to immunotherapy, offering a potential new treatment option for patients with limited choices following failure of standard PD-1 (search)/L1 therapies.
Phase 3 Dublin-3 Study Results
BeyondSpring's Phase 3 Dublin-3 study evaluated Plinabulin in combination with docetaxel in second/third line advanced and metastatic NSCLC (search) patients with EGFR (search) wild-type. The final efficacy data, published in The Lancet Respiratory Medicine on September 9, 2024, showed that the plinabulin/docetaxel combination significantly improved overall survival, progression-free survival, and objective response rate compared with docetaxel alone.
Additionally, the combination reduced the occurrence of severe (Grade 4) neutropenia, a common and serious side effect of docetaxel. The study demonstrated a statistically significant overall survival benefit in second- and third-line NSCLC (search) (EGFR (search) wild-type) compared to standard docetaxel treatment, supporting the company's plan to submit regulatory applications in China and other regions.
Safety Profile and Clinical Development
Safety data from the Dublin-3 study, presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, indicated a favorable safety profile with adverse effects that were manageable and consistent with expectations for patients in this setting. The findings offered detailed insights into the treatment's tolerability and potential for addressing unmet needs in advanced lung cancer (search) care.
Strategic Implications
BeyondSpring is exploring Plinabulin's potential as an immuno-oncology agent beyond its established role in NSCLC (search) treatment. The ongoing Phase 2 studies have shown promising results when Plinabulin is combined with PD-1 (search) inhibitors, suggesting it may help re-sensitize tumors that have become resistant to current therapies. This dual mechanism of action positions Plinabulin as a potentially transformative treatment for patients with treatment-resistant cancers across multiple tumor types.